Results 191 to 200 of about 210,784 (393)

Targeting the Menin–KMT2A interaction in leukemia: Lessons learned and future directions

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Chromosomal rearrangements involving the Mixed Lineage Leukemia gene (MLL1, KMT2A) are defining a genetically distinct subset in about 10% of human acute leukemias. Translocations involving the KMT2A‐locus at chromosome 11q23 are resulting in the formation of a chimeric oncogene, where the N‐terminal part of KMT2A is fused to a variety of ...
Florian Perner   +3 more
wiley   +1 more source

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

open access: yesInternational Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner   +7 more
wiley   +1 more source

Integrative omics approaches to uncover liquid‐based cancer‐predicting biomarkers in Lynch syndrome

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Lynch syndrome (LS) significantly increases lifetime cancer risk, necessitating innovative approaches for risk stratification. Current risk assessment methods, however, fail to integrate data from different biological systems, which may be influenced by lifestyle factors.
Minta Kärkkäinen   +9 more
wiley   +1 more source

Embryo-maternal cross-talk: key players in successful implantation and live birth rates. [PDF]

open access: yesReprod Biol Endocrinol
Karimi S   +3 more
europepmc   +1 more source

Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol

open access: yesInternational Journal of Cancer, EarlyView.
What's New? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy